{"id":508806,"date":"2020-09-28T14:00:01","date_gmt":"2020-09-28T14:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=508806"},"modified":"2020-09-28T14:00:01","modified_gmt":"2020-09-28T14:00:01","slug":"binge-eating-disorders-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/binge-eating-disorders-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_508806.html","title":{"rendered":"Binge (Eating) Disorders Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Binge (Eating) Disorders Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Binge (Eating) Disorders Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Binge (Eating) Disorders Pipeline Insight, 2020&#8242;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight has launched a new report on<strong> &#8220;Binge (Eating) Disorders Pipeline Insight, 2020&#8221;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/binge-disorders-pipeline-insight?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\"><strong>Binge Disorders Pipeline Insight, 2020<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Binge Disorders&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Binge Disorders&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Binge Disorders&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Binge Disorders&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Binge Disorders&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Binge Disorders&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>List of top key players in binge eating disorder drug market report are: &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\">\u25cf Roche<\/p>\n<p style=\"text-align: justify;\">\u25cf Chronos Therapeutics<\/p>\n<p style=\"text-align: justify;\">\u25cf Heptares<\/p>\n<p style=\"text-align: justify;\">\u25cf Novo Nordisk<\/p>\n<p style=\"text-align: justify;\">\u25cf Omeros Corp<\/p>\n<p style=\"text-align: justify;\">\u25cf Sunovion Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">\u25cf Opiant Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Binge Disorders&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Binge Disorders&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Binge Disorders&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Binge Disorders&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Binge Disorders<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/binge-disorders-pipeline-insight?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\"><strong>Binge-eating disorder<\/strong><\/a> is a serious eating disorder in which you frequently consume unusually large amounts of food and feel unable to stop eating.<\/p>\n<p style=\"text-align: justify;\">Almost everyone overeats on occasion, such as having seconds or thirds of a holiday meal. But for some people, excessive overeating that feels out of control and becomes a regular occurrence crosses the line to binge-eating disorder.<\/p>\n<p style=\"text-align: justify;\">When you have binge-eating disorder, you may be embarrassed about overeating and vow to stop. But you feel such a compulsion that you can&#8217;t resist the urges and continue binge eating. If you have binge-eating disorder, treatment can help.<\/p>\n<p style=\"text-align: justify;\"><strong>Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\">Most people with binge-eating disorder are overweight or obese, but you may be at a normal weight. Behavioral and emotional signs and symptoms of binge-eating disorder include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Eating unusually large amounts of food in a specific amount of time, such as over a two-hour period<\/li>\n<li>Feeling that your eating behavior is out of control<\/li>\n<li>Eating even when you&#8217;re full or not hungry<\/li>\n<li>Eating rapidly during binge episodes<\/li>\n<li>Eating until you&#8217;re uncomfortably full<\/li>\n<li>Frequently eating alone or in secret<\/li>\n<li>Feeling depressed, disgusted, ashamed, guilty or upset about your eating<\/li>\n<li>Frequently dieting, possibly without weight loss<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for Binge Disorders treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of Binge Disorders?<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of Binge Disorders?<\/li>\n<li>How many Binge Disorders emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Binge Disorders?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Binge Disorders market?<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of Binge Disorders?&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Binge Disorders therapies?<\/li>\n<li>What are the clinical studies going on for Binge Disorders and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for Binge Disorders?<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of Binge Disorders?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Binge Disorders&nbsp;<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.1. Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.3. Binge Disorders Symptoms<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.4. Causes<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.6. Binge Disorders Diagnosis&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>3. Binge Disorders&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">3.1. Binge Disorders Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>4. Binge Disorders&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.1. Binge Disorders&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2. Binge Disorders&nbsp;Collaboration Deals<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2.3. Binge Disorders&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\"><strong>6. Binge Disorders Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Binge Disorders Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Binge Disorders Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Binge Disorders&nbsp;Product Profiles<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>14. Binge Disorders&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Binge Disorders&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\"><strong>17. Binge Disorders&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Binge Disorders&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Binge Disorders&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;https:\/\/www.delveinsight.com\/sample-request\/binge-disorders-pipeline-insight<\/strong>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=binge-eating-disorders-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/binge-disorders-pipeline-insight?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/binge-disorders-pipeline-insight?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/binge-disorders-pipeline-insight?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=binge-eating-disorders-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Binge (Eating) Disorders Pipeline Insight, 2020&#8242; (Albany, US) DelveInsight has launched a new report on &#8220;Binge (Eating) Disorders Pipeline Insight, 2020&#8221;&nbsp; &#8220;Binge Disorders Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/binge-eating-disorders-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_508806.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-508806","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=508806"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=508806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=508806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=508806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}